http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104211605-B

Outgoing Links

Predicate Object
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C213-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C213-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C65-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C51-43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C51-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C215-44
filingDate 2014-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2016-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2016-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-104211605-B
titleOfInvention A kind of Transbroncho and m-Salicylic acid eutectic and preparation method thereof
abstract The invention belongs to technical field of pharmaceutical co-crystal, be specifically related to a kind of novel Transbroncho pharmaceutical co-crystals and preparation method thereof.The Transbroncho pharmaceutical co-crystals spacer that the present invention prepares is oblique system, and a Transbroncho molecule passes through, together with hydrogen bonded, to form the elementary cell of Transbroncho pharmaceutical co-crystals with a m-Salicylic acid.The solvent that eutectic preparation process is selected is the mixed system of first alcohol and water, and employing method is solvent room temperature volatilization method, because the boiling point of selected solvent is relatively low, therefore in the process of solvent evaporates, has crystal separate out.Pharmaceutical co-crystals prepared by the present invention, outside the speciality such as the eliminating of the inner thick secretions of the promotion respiratory tract maintaining Transbroncho and the delay of minimizing mucus, is significantly improved in its stability.
priorityDate 2014-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-3536713-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-3950393-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2132
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419538410
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID702
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458392451
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411932836
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457623688
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7420
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID887
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419510606
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419493733

Total number of triples: 28.